- Improved quality of life in 사설 바카라 management, regardless of antibody presence
- Notable 사설 바카라 reduction after 13 weeks of HEMLIBRA administration
[by Ji, Yong Jun] JW Pharmaceutical revealed on February 20 that research findings indicated the hemophilia A treatment, ‘HEMLIBRA’ improves patients’ quality of life, particularly in relation to 사설 바카라, published in the international academic journal ‘Haemophilia’.
HEMLIBRA is an innovative novel drug with a mechanism that mimics the lack of blood clotting factor VIII in 사설 바카라 A patients. It utilizes bispecific antibody technology, which simultaneously binds to blood clotting factors IX and X.
It can be used by both antibody patients who have developed resistance to existing treatments (such as factor VIII preparations) and non-antibody patients. Its preventive effect lasts up to four weeks with a single subcutaneous injection. As of June 2024, around 25,000 사설 바카라 A patients around the world were receiving HEMLIBRA treatment.
The research team, led by Professor Cedric Hermans of the Catholic University of Louvain in Belgium, conducted a study involving 504 patients with severe hemophilia A who participated in the global phase 3 clinical trial of HEMLIBRA. The team monitored changes in joint and swelling 사설 바카라 for 78 weeks following the administration of HEMLIBRA to adolescents and adults aged 12 years or older.
Approximately 80% of bleeding episodes in hemophilia patients occur in the joints, which is the primary cause of joint 사설 바카라. A previous study found that 86% of 381 hemophilia patients with a history of joint bleeding experienced either acute or chronic 사설 바카라. This 사설 바카라 not only impacts physical activity but also affects mental health, leading to a decreased quality of life.
The study showed that the percentage of patients reporting 'no or almost no swelling 사설 바카라' increased from 37.0% before treatment to 84.0% by the 13th week of administration. The proportion of patients who reported ‘no or little joint 사설 바카라’ rose from 30.0% to 61.0%, and those who indicated ‘no or little 사설 바카라 and discomfort’ improved from 71.0% to 81.0% over the same period. These 사설 바카라 relief effects lasted up to 78 weeks.
Notably, in patients who had received preventive treatment with existing factor VIII therapies for more than six months, the percentage of those reporting ‘no or little 사설 바카라’ related to swelling and 사설 바카라 increased by 41.7% after 13 weeks of HEMLIBRA administration. Similarly, the percentage of patients experiencing ‘no or little 사설 바카라’ increased by 29.2%.
“Continuous preventive treatment with HEMLIBRA reduces joint bleeding and intra-articular rebleeding, which likely contributes to alleviating 사설 바카라 associated with synovial inflammation,” the research team explained. “This suggests that HEMLIBRA preventive treatment can offer additional benefits, such as improved quality of life, beyond the reduced bleeding rate seen with factor VIII preventive treatment.”
“Through this study, we hope that HEMLIBRA preventive therapy can contribute to improving the quality of life of 사설 바카라 patients, in addition to its function in preventing bleeding,” a JW Pharmaceutical official said.